Description: Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The companys lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma. Verona Pharma plc is based in London, the United Kingdom.
Home Page: www.veronapharma.com
VRNA Technical Analysis
3 More London Riverside
London,
SE1 2RE
United Kingdom
Phone:
44 20 3283 4200
Officers
| Name | Title |
|---|---|
| Dr. David S. Zaccardelli | Pres, CEO & Exec. Director |
| Mr. Mark W. Hahn | Chief Financial Officer |
| Dr. Kathleen A. Rickard | Chief Medical Officer |
| Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA | Gen. Counsel |
| Ms. Victoria Stewart | Director of Communications |
| Mr. Matthew Casbon | VP of Sales, Marketing & Training |
| Ms. Ostra Jewell | Sr. VP of HR |
| Dr. Peter Spargo | Sr. VP of Chemistry Manufacturing & Controls |
| Dr. Tara Rheault M.P.H., Ph.D. | Sr. VP of R&D |
| Ms. Nina Church | Exec. Director of Global Clinical Devel. |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.1364 |
| Price-to-Sales TTM: | 18.5606 |
| IPO Date: | 2017-04-27 |
| Fiscal Year End: | December |
| Full Time Employees: | 24 |